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Abstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) 
is deeply involved in the pathology of rheumatoid arthritis (RA). Tocilizumab is a humanized 
anti-human IL-6 receptor antibody that binds to soluble and membrane-bound IL-6 receptor, 
and at detectable levels in blood, tocilizumab is capable of almost completely blocking the 
transmembrane signaling of IL-6. In clinical trials for patients with RA in Japan, tocilizumab 
monotherapy has shown clinical efﬁ  cacy equaling that of tumor necrosis factor (TNF) inhibi-
tor in combination with methotrexate, and in an extension study in patients who responded to 
tocilizumab, almost no patients showed a decrease in the efﬁ  cacy of tocilizumab. Evidence 
obtained in a phase III study in Japan demonstrated that tocilizumab monotherapy had a sig-
niﬁ  cant inhibitory effect on the progression of structural joint damage compared with that of 
conventional disease modifying antirheumatic drugs (DMARDs). Furthermore it has been shown 
that tocilizumab has an excellent ability to suppress serum amyloid A levels and could therefore 
be an important therapeutic strategy in amyloid A amyloidosis secondary to rheumatic diseases. 
The safety proﬁ  le of tocilizumab appears to be satisfactory. However, several serious infections 
were also reported, and careful monitoring is therefore important during use.
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Introduction
Rheumatoid arthritis (RA) is a chronic inﬂ  ammatory disease that causes inﬂ  ammation 
in intra-articular synovial tissue, producing pain and swelling. Persistent synovitis 
produces destruction of bone and cartilage, adversely affecting the activities of daily 
living. Extra-articular complications also often occur, thereby eliciting a worsening of 
the prognosis. The causes of RA are still obscure, but research using disease models 
has shown that proinﬂ  ammatory cytokines such as tumor necrosis factor-α (TNF-α) 
and interleukin (IL)-6 or IL-1 play key roles in its pathogenesis. The anti-TNF agents 
inﬂ  iximab, etanercept, and adalimumab are presently used in the treatment of RA, and 
compared with methotrexate (MTX) and other conventional disease modifying anti-
rheumatic drugs (DMARDs), not only yield greater reductions in the level of disease 
activity, but also have the beneﬁ  t of inhibiting or partially improving the progression 
of structural joint damage, and are therefore aggressively used in patients with severe 
disease activity. For patients with disease that is resistant to TNF inhibitors, cytotoxic 
T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) and the human IgG1 fusion protein: 
abatacept, and the anti-CD20 chimeric antibody: rituximab are used mainly in the 
US and Europe, and while they are recognized as useful, inadequate responses are 
still seen in no small number of cases. Meanwhile, it has been shown in clinical trials 
conducted to date that the humanized anti-IL 6 receptor antibody: tocilizumab has an 
excellent improvement effect on disease activity, an inhibitory effect on joint destruc-
tion, and therapeutic beneﬁ  t for amyloid A (AA) amyloidosis. Tocilizumab has been Biologics: Targets & Therapy 2008:2(1) 76
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ﬁ  led for approval in Japan and is currently completing the 
global phase III clinical development program for registra-
tion in other countries. With its mechanism of action unlike 
that of other biologic agents and its unique characteristics, 
expectations are high for tocilizumab as a new therapeutic 
tool in the treatment of RA.
Pathological role of IL-6 in RA
Originally identiﬁ  ed in 1982 as an antigen-nonspeciﬁ  c B cell 
differentiation factor produced by activated mononuclear 
cells (Yoshizaki et al 1982), IL-6 is a cytokine cloned in 
1986 by Hirano et al (1986). Subsequent research has shown 
that IL-6 is a pleiotropic cytokine with diverse physiological 
actions, regulating the immune response, inﬂ  ammation, bone 
metabolism, and hematopoiesis (Figure 1). In the joints 
of patients with RA, IL-6 is produced in large quantities 
from synovial cells and macrophages, eliciting polyclonal 
hypergammaglobulinemia and the emergence of autoanti-
bodies as a result of B cell differentiation. Additionally, via 
enhanced expression of intercellular adhesion molecule-1, 
IL-6 promotes the inﬁ  ltration of inﬂ  ammatory cells into 
synovial tissue, and acting synergistically with TNF-α 
and IL-1, promotes angiogenesis as a result of increased 
production of vascular endothelial growth factor (VEGF) 
(Nakahara et al 2003). IL-6 also promotes increased 
production of metalloproteinases (Roux-Lombard et al 
2001) and the activation of osteoclasts (Kotake et al 1996) is 
involved in the destruction of cartilage and bone. Addition-
ally, overproduction of IL-6 leads to increases in acute phase 
reactants such as C-reactive protein (CRP), serum amyloid 
A (SAA), hypoalbuminemia, increased platelet count, and 
anemia, and long-term persistence of such overproduction 
is thought to be involved in the development of AA amy-
loidosis, a serious complication of RA. Recent research has 
also demonstrated that there are 4 subsets of helper T cells: 
Th1, Th2, and Th17, which produces IL-17 and other cyto-
kines that play a key role in inﬂ  ammation, and regulatory 
T cell (Treg), which is involved in negative immune response 
control. Th17 is induced when transforming growth factor-β 
(TGF-β) and IL-6 are present during antigen stimulation 
of naïve T cells. Since the development of arthritis can be 
inhibited by blocking IL-17, Th17 plays a crucial role in 
arthritis models (Lubberts et al 2004). In contrast, Treg is 
only induced when TGF-β is added to naïve T cells. In a 
model of arthritis induced by passive transfer of collagen-sen-
sitized T cells, the onset of arthritis was inhibited when Treg 
was added simultaneously (Morgan et al 2005). IL-6 inhibits 
differentiation of Treg, and increases the number of Th17 
cells. This demonstrates that IL-6 is an extremely important 
cytokine in the pathogenesis of RA, in which activated T cells 
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Figure 1 Pathological roles of interleukin-6 in rheumatoid arthritis. Constitutive overproduction of interleukin-6, a pleiotropic cytokine that regulates the immune system, 
inﬂ  ammation, hematopoiesis, and bone metabolism, is thought to play pathologic roles in rheumatoid arthritis.
Abbreviations: VEGF, vascular endothelial growth factor; ICAM-1, intercellular adhesion molecule-1; Th17, interleukin-17 producing CD4+ T cell; Treg, CD4+CD25+ regula-
tory T cell; RF, rheumatoid factor; CRP, C-reactive protein; SAA, serum amyloid A; RBC, red blood cell.Biologics: Targets & Therapy 2008:2(1) 77
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inﬂ  ammation, bone metabolism, hematopoiesis, and the 
neuroendocrine system.
Tocilizumab is a recombinant monoclonal antibody that 
has been humanized by complementarity determining region 
(CDR) grafting of a murine anti-human IL-6R antibody 
onto human IgG1. Tocilizumab inhibits the induction of 
biological activity due to IL-6 in cells that have expressed 
both membrane-bound IL-6R and gp130 molecules, and 
also inhibits the induction of biological activity due to 
IL-6/IL-6R complex formation in cells that express gp130 
alone. Furthermore, since it has the capacity to dissociate 
IL-6/IL-6R complexes that have already formed, it exhibits 
an extremely effective blocking action on IL-6 signal trans-
duction (Figure 2).
Clinical trials of tocilizumab for RA
Phase I clinical trial (UK)
A phase I clinical trial to conﬁ  rm the safety and efﬁ  cacy of 
tocilizumab in single-dose administration was conducted 
in the United Kingdom (Choy et al 2002). A single dose 
of tocilizumab 0.1, 1, 5, 10 mg/kg or placebo was given 
are involved. In contrast, even in the presence of TGF-β, 
TNF and IL-1 show no activity to induce Th17 or inhibit the 
differentiation of Treg.
Mode of action of tocilizumab
IL-6 has a unique receptor system, and while IL-6 receptor 
(R) speciﬁ  cally binds to IL-6, it does not have a direct 
involvement in signal transduction. IL-6 forms a complex 
by binding to IL-6 R on the cell membrane, which then 
combines with gp130, which also resides on the cell mem-
brane, forming a homodimer and giving rise to intracellular 
signal transduction. Furthermore, IL-6R also exists as a 
soluble from. After forming a complex with IL-6, soluble (s) 
IL-6R can also combine with gp130 on the cell membrane 
and enables signaling (Ward et al 1994). s IL-6R is present in 
the blood of healthy individuals at a concentration of several 
tens of ng/mL, and if the cells express gp130, IL-6 signaling 
can take place, even in the absence of IL-6R expression on 
the cell membrane. Reﬂ  ecting this characteristic, the effects 
of IL-6 are diverse, and it is thought to have an extensive 
regulatory role, with involvement in the immune response, 
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Figure 2 Signal transduction of interleukin (IL)-6 /IL-6 receptor (R) complex via gp130 and the mechanism of signal transduction blockage by tocilizumab. IL-6 signal is medi-
ated via IL-6R on the cell surface or soluble form of IL-6R, followed by dimerization of the signal transducer gp-130, which is bound to the IL-6/IL-6R complex. Tocilizumab 
inhibits the binding of IL-6 to IL-6R or sIL-6R.Biologics: Targets & Therapy 2008:2(1) 78
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to a total of 45 patients with RA, and an analysis of 
pharmacokinetics and evaluation of RA disease activity 
were performed at 2 weeks post-dose. An ACR20 response, 
indicating 20% improvement in disease activity according 
to the American College of Rheumatology (ACR) criteria, 
was achieved by 55.6% of patients in the 5-mg/kg group, a 
statistically signiﬁ  cant difference from that in the placebo 
group. Furthermore, CRP levels normalized in all patients in 
the 5 and 10-mg/kg groups. There were no serious adverse 
reactions related to tocilizumab.
Phase I/II clinical trials (Japan)
A phase I/II clinical trial to investigate the pharmacokinetics 
and safety of tocilizumab in repeated administration was 
conducted in Japan (Nishimoto et al 2003). In this trial, 
tocilizumab 2, 4, or 8 mg/kg was administered by intravenous 
drip infusion every 2 weeks for a total of 3 times. Pharmaco-
kinetics, safety, and clinical efﬁ  cacy were evaluated, and if 
there were no safety concerns, treatment was continued and 
RA activity was re-evaluated at 6 months. At 4 and 8 mg/kg, 
tocilizumab showed a tendency to accumulate in blood, and 
the half-life after 3 infusions of 8 mg/kg was approximately 
240 hours, approaching that of human IgG. Both CRP and 
SAA were completely normalized in all patients in whom 
tocilizumab was detected in blood at the trough concentra-
tion. Based on these ﬁ  ndings, it was conﬁ  rmed that IL-6 is 
a cytokine that is indispensable for the production of CRP 
and SAA. While this was an open-label trial, the ACR20 
response was 60% and the ACR50 response was 13% at 
6 weeks, and with continued treatment, the ACR20 response 
was 86% and the ACR50 response was 33% at 6 months. 
MTX was not coadministered, and no neutralizing antibod-
ies to tocilizumab were detected, conﬁ  rming the advantage 
of a humanized antibody. In repeated administration, there 
was no attenuation of effects, nor were there any serious 
adverse events.
Late phase II clinical trial (Japan)
A late phase II clinical trial, conducted as a multicenter, 
double-blind, placebo-controlled trial, was started in Japan 
in 2001 (Nishimoto et al 2004). One hundred sixty-four RA 
patients with inadequate responses to one or more antirheu-
matic drugs or immunosuppressants were randomly assigned 
to 3 treatment groups: placebo, 4 mg/kg, and 8 mg/kg. Tocili-
zumab or placebo was intravenously infused every 4 weeks, 
a total of 3 times, and RA activity was evaluated at 12 weeks. 
This regimen was designed on the assumption that the blood 
concentration could be maintained in treatment at 8 mg/kg 
every 4 weeks, based on a pharmacokinetics simulation 
using the results of the phase I/II trial. The median number 
of antirheumatic drugs already used by patients before entry 
into the trial was 4–5, and the mean duration of disease was 
about 8 years, together indicating that most of these patients 
had progressed disease. At 12 weeks, an ACR20 response 
was achieved by 78% of patients in the 8-mg/kg group and 
57% of patients in the 4-mg/kg group, versus a meager 11% 
of patients in the placebo group. Hence, improvement of the 
RA activity in the 8 mg/kg group was statistically signiﬁ  cant 
in comparison with that in the placebo and 4-mg/kg groups 
(p   0.001, p = 0.02) (Figure 3). Furthermore, both the ACR50 
and ACR70 responses in the 8-mg/kg group were superior to 
those in the placebo group (p   0.001, p = 0.002). Evaluation 
using the DAS28 (Disease Activity Score according to the 
European League Against Rheumatism [EULAR] improve-
ment criteria) also showed that the response was good or 
moderate for 90.9% of patients in the 8-mg/kg group. The 
safety analysis showed that the incidences of adverse events 
were not dose dependent: 56%, 59%, and 51% of the patients 
in placebo, 4 mg/kg, and 8 mg/kg groups, respectively. The 
most common adverse event was upper respiratory infec-
tion (common cold), but there were no differences among 
the groups in its incidence. Infusion reactions were seen 
rarely, but these were mild and transient. Serious adverse 
events were reported for 3 patients receiving tocilizumab and 
2 patients receiving placebo. For 1 patient in the tocilizumab 
group, chronic, active Epstein-Barr virus (EBV) infection 
was reactivated after the ﬁ  rst infusion of 8 mg/kg, follow-
ing which hemophagocytic syndrome developed, and death 
ensued on the 61st day (Ogawa et al 2006). Before treatment 
with tocilizumab, this patient had shown variations in hepatic 
function and CRP, as well as elevated EBV-DNA levels in 
plasma. Two weeks after treatment with tocilizumab, hepatic 
function was increased in association with elevated plasma 
EBV-DNA, and hemophagocytic syndrome occurred. It was 
later ascertained that this patient had had Hodgkin’s disease 
before treatment. The other serious adverse events were 
allergic pneumonitis and infection secondary to a grade 2–3 
burn on the leg, and both were cured by medication. Among 
abnormal laboratory values, increased total cholesterol (TC) 
was seen in 44% of patients receiving tocilizumab. However, 
the increase did not persist, and HDL cholesterol (HDL-C) 
was similarly elevated. Long-term evaluations of safety 
will be required to assess any change in the risk of ischemic 
heart disease. Such an increase in TC concentration was also 
subsequently reported in treatment with a TNF-α inhibitor 
(Kiortsis et al 2006), and therefore it may be secondary to the Biologics: Targets & Therapy 2008:2(1) 79
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improvement in inﬂ  ammation. Liver function disorders and 
decreases in white blood cell count were also observed in the 
tocilizumab group, but most were moderate or less severe, 
and resolved without any treatment. Anti-tocilizumab anti-
bodies were detected in 2 patients treated with tocilizumab, 
but both were asymptomatic. No induced production of 
anti-nuclear antibodies (ANA) or anti-DNA antibodies was 
seen, as is occasionally reported in treatment with TNF-α 
inhibitors.
Phase II clinical trial (Europe; the Chugai 
humanized anti-Human recombinant 
interleukin-6 monoclonal antibody 
[CHARISMA] study)
This double-blind, randomized, 16-week trial included 359 
patients with RA who had not responded adequately to  4 
weeks of methotrexate (Maini et al 2006). Patients received 4 
infusions of tocilizumab 2, 4, or 8 mg/kg every 4 weeks plus 
either MTX or placebo once weekly, or 4 placebo infusions 
every 4 weeks plus MTX once weekly. An ACR20 response 
was achieved by 61% and 63% of patients who received 
4 and 8 mg/kg of tocilizumab monotherapy, respectively, and 
by 63% and 74% of patients who received 4 and 8 mg/kg of 
tocilizumab plus MTX, respectively. The efﬁ  cacy of TNF 
inhibitors is increased by concomitant treatment with MTX, 
but the authors found that the beneﬁ  ts of tocilizumab were 
similar with and without concomitant MTX. Tocilizumab was 
generally well tolerated; about 50% of patients experienced 
an adverse event, although most were mild or moderate. 
Some tocilizumab-treated individuals experienced clinically 
signiﬁ  cant increases in transaminase levels, which seemed 
to be exacerbated by MTX. Dose-dependent increases in 
bilirubin and TC, and decreased neutrophil count were also 
observed. Overall, anti-tocilizumab antibodies developed 
in 25 patients, all of whom were in the group receiving 
either 2 mg/kg or 4 mg/kg of tocilizumab as monotherapy; 
anti-tocilizumab antibodies developed in none of the 
patients receiving treatment with 8 mg/kg of tocilizumab or 
combination therapy.
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Figure 3 The incidence of a 20% improvement in disease activity according to the American College of Rheumatology (ACR) criteria at week 12. Tocilizumab treatment 
signiﬁ  cantly improved all measures of disease activity in the ACR core set, and a dose-response relationship was observed between the 4-mg and 8-mg groups. Adapted with 
permission from Nishimoto N, Yoshizaki K, Miyasaka N, et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, 
double-blind, placebo-controlled trial. Arthritis Rheum, 50:1761–9. Copyright © 2004. Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.
Abbreviation: TOC, tocilizumab.Biologics: Targets & Therapy 2008:2(1) 80
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Phase III clinical trial (Japan)
Study of active controlled monotherapy used for 
rheumatoid arthritis, an IL-6 inhibitor (SAMURAI)
This was an X-ray reader-blinded, open-label, random-
ized, controlled trial in RA patients with disease duration 
less than 5 years, and inadequate to at least 1 DMARD 
(Nishimoto et al 2007). Three hundred and six RA patients 
with inadequate response to DMARDS were randomized to 
tocilizumab monotherapy (tocilizumab group, 158 patients) 
or conventional therapy (conventional DMARDs group, 
148 patients). Patients in the tocilizumab group received 
8 mg/kg of tocilizumab every 4 weeks, a total of 13 times, 
while those in the control group received conventional 
treatment with any conventional DMARDs, except for 
TNF inhibitors or leﬂ  unomide. At week 52, patients in the 
tocilizumab group showed statistically less radiographic 
progression, as measured by the change in total modiﬁ  ed 
Sharp score (TSS), than those receiving DMARDs (2.3 ± 
5.6 versus 6.1 ± 11.4; p = 0.001). Tocilizumab was superior 
to DMARDs in preventing both erosion and joint space nar-
rowing (p   0.001 and p = 0.018 respectively). This study 
showed the superiority of blocking IL-6 with tocilizumab 
compared with conventional DMARDs in inhibiting radio-
graphic progression.
Study of active controlled tocilizumab monotherapy 
for rheumatoid arthritis patients with inadequate 
response to methotrexate (SATORI)
This phase III double-blind controlled trial investigated the 
efﬁ  cacy and safety of tocilizumab in monotherapy in patients 
with active RA who had inadequate responses to MTX 
treatment (Nishimoto et al 2006a). Patients with active RA 
despite receiving MTX 8 mg/week, the recommended dose 
in Japan, during the 8-week screening period, were random-
ized in a ratio of 1:1 to receive either tocilizumab 8 mg/week 
plus MTX placebo (tocilizumab group) or tocilizumab 
placebo plus MTX 8 mg/week (MTX group) for 24 weeks. 
Of 127 patients enrolled, 125 patients received at least 
one dose of the study drugs (61 patients in the tocilizumab 
group and 64 patients in the MTX group). At 24 weeks, the 
ACR20 response rate was statistically signiﬁ  cantly higher 
in the tocilizumab group than in the MTX group (80.3% 
versus 25.0%, p   0.001). Patients in the tocilizumab group 
also had signiﬁ  cantly higher ACR50 and ACR70 response 
rates than patients treated with MTX (49.2% versus 10.9%, 
p   0.001 and 29.5% versus 6.3%, p   0.001, respectively). 
Seven patients and 31 patients were withdrawn from the 
tocilizumab and MTX groups, respectively. Withdrawal 
due to adverse events ( tocilizumab n = 2, MTX n = 3) as 
well as the occurrence of serious adverse events (tocili-
zumab n = 4, MTX n = 3) were similar between the groups. 
Increased lipids were noted in the tocilizumab group but 
became stable at around the upper limit of normal range. 
The frequency of liver function test abnormalities as adverse 
events was higher in the MTX group (ALT increase 10.9%) 
but the severity was grade 1 in most cases. No tuberculosis 
was reported. In this study tocilizumab in monotherapy for 
24 weeks signiﬁ  cantly improved signs and symptoms and 
was well tolerated in patients who had active RA despite 
receiving MTX.
Advantages of tocilizumab 
and future prospects
The late phase II and two phase III clinical trials in 
Japan showed similarly reproducible outstanding results 
(Nishimoto et al 2006b) (Table 1). From these ﬁ  ndings, it 
can be anticipated that monotherapy with tocilizumab 8 mg/
kg will yield equivalent clinical efﬁ  cacy to TNF inhibi-
tor in combination with MTX. In the CHARISMA study 
conducted in Europe, the difference in ACR20 response 
between the tocilizumab monotherapy 8-mg/kg group and 
the MTX plus tocilizumab 8-mg/kg combination therapy 
group was not signiﬁ  cant. However, the numbers of patients 
achieving ACR50 and ACR70 responses tended to be higher 
in the combination therapy group. A detailed evaluation of 
the clinical efﬁ  cacy, safety, and inhibitory effect on bone 
and cartilage destruction of combination therapy with MTX 
plus tocilizumab will be revealed in the phase III trials that 
are currently underway in Europe, North America, and else-
where. Noteworthy aspects of treatment with tocilizumab 
are that SAA and CRP levels were normalized in nearly all 
the patients in whom pre-infusion trough levels of the drug 
can be detected in blood, that is, tocilizumab can be mea-
sured in blood before treatment. In the phase III SATORI 
Table 1 DAS28 remission ( 2.6)% improvement scores among 
tocilizumab’s clinical studies. Tocilizumab treatment signiﬁ  cantly 
improved the measures of DAS28 scores compared to the control 
group. Adapted from Nishimoto et al (2006b)
  Late  P  II   SATORI   SAMURAI
  T C T C T C
12 weeks  18.2  0  34.3  1.6  29.3  1.4
24  weeks  N.A N.A 41.0 1.6  40.1  4.1
52  weeks  N.A N.A N.A N.A 58.6  3.4
Notes: SATORI = Study of active controlled monotherapy for rheumatoid arthritis 
patients with inadequate response to methotrexate; SAMURAI = Study of active 
controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor.Biologics: Targets & Therapy 2008:2(1) 81
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trial conducted in Japan, patients received 8 mg/kg every 
4 weeks for 24 weeks, and the patients who were unable to 
achieve CRP normalization were those in whom tocilizumab 
could not be detected in blood at trough levels. Trough 
levels could not be maintained in 10%–20% of patients, 
and if it were possible to adjust the dosing interval in these 
patients so that the trough level could be maintained, it is 
predicted that the improvement rate in clinical results would 
increase. As regards prognostic factors of joint destruction 
in the SAMURAI trial, the percentage change in matrix 
metalloproteinase-3 (MMP-3) at 12 weeks after starting 
treatment was an independent prognostic factor for the ero-
sion score at 52 weeks by the modiﬁ  ed Sharp method, and the 
percentage changes in CRP, MMP-3, and serum N-terminal 
propeptide of type II A collagen at 12 weeks after starting 
treatment have been reported to be signiﬁ  cantly indepen-
dent prognostic factors for the joint space narrowing (JSN) 
score (Hashimoto et al 2007). In the SAMURAI trial, the 
protocol also called for infusion of 8 mg/kg every 4 weeks, 
and the fact that CRP was identiﬁ  ed as a risk factor for 
the JSN score can be considered to be a result that sug-
gests the importance of maintaining pre-infusion trough 
levels for preventing destruction of cartilage and joints. 
Since tocilizumab is a humanized rather than a chimeric 
antibody, it is unlikely that anti-tocilizumab antibodies 
will be produced. In the CHARISMA study, however, in 
the low-dose groups treated with tocilizumab monotherapy 
2 mg/kg and 4 mg/kg, the concentration of tocilizumab 
in blood could not be detected at the trough level, and in 
these groups, anti-tocilizumab antibodies were produced in 
a small number of patients. In the SAMURAI trial, anti-
tocilizumab antibodies were produced in 4 patients, but the 
trough blood concentration could not be detected in 3 of 
these patients (Nishimoto et al 2007), and it is considered 
that maintaining the pre-infusion trough level is critical 
to improving the efﬁ  cacy rate and reducing infusion reac-
tions. These patients were withdrawn in accordance with 
the study protocol. Furthermore, in patients in whom the 
treatment was effective once, there was almost no decrease 
in the efﬁ  cacy of tocilizumab, in other words the escape 
phenomenon was absent in the extension study, and this 
should be a major advantage of tocilizumab. Hence, when 
using tocilizumab in the post-approval clinical setting, it 
will be advisable in the early period after infusion to either 
monitor the blood concentration of tocilizumab or to adjust 
the dosing interval for individual patients using CRP or 
SAA as surrogate markers so that the trough level is main-
tained. Furthermore, since the capacity of tocilizumab to 
normalize values of CRP and SAA is clearly superior to 
that of TNF inhibitors (Hagiwara et al 2004, 2005; Okuda 
et al 2007), the advantage in treatment of AA amyloidosis, 
a serious complication of rheumatic diseases (Okuda et al 
2006) should be emphasized.
However, as well as yielding normalization of CRP and 
SAA levels, inhibition of IL-6 by tocilizumab makes IL-6-
induced fever and general fatigue less prominent. Therefore, 
it is vital to undertake careful clinical observations and 
monitoring so that discovery after the onset of infection is not 
delayed and the infection does not become more severe.
Turning now to the effect on tuberculosis seen in treat-
ment with TNF inhibitors, it should be noted that while TNF 
plays an important role in granuloma formation (Roach 
et al 2002), IL-6 has no such action. For tuberculosis 
therefore, it is considered that there will be little likelihood 
of recrudescence in patients with previous tuberculosis 
infection, and this is also considered to be an advantage 
over TNF inhibitors. As regards abnormal variations in 
laboratory values, increased TC was seen in about 40% 
of patients in the tocilizumab treatment group, a ﬁ  nding 
that was dose-dependent. However, since the increased 
TC value subsequently leveled off, and HDL-C was also 
increased, the atherogenic index was unchanged. Increased 
serum IL-6 levels have been associated with future risk of 
cardiovascular events (Fisman et al 2006), but long-term 
epidemiological surveillance will be needed to ascertain 
whether tocilizumab acts protectively against or promotes 
cardiovascular events. The emergence of ANA or anti-DNA 
antibodies occasionally observed with TNF inhibitor was 
also not evident in either trial in treatment with tocilizumab. 
Another interesting report notes that when NZB/NZW F1 
mice with a spontaneous autoimmune disease that resembles 
systemic lupus erythematosus (SLE) were administered 
with anti-mouse IL-6 receptor antibodies, the production 
of IgG-class anti-DNA antibodies was almost completely 
inhibited resulting in the inhibition of nephritis, hence the 
development of nephritis was inhibited, and the survival 
time prolonged (Mihara et al 1998). Tocilizumab therefore 
promises to be effective in the treatment of SLE and other 
autoimmune diseases.
Footnote
These ﬁ  ndings have been published in the primary publica-
tions referred to, and listed in the reference list.
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